Opus Genetics files audited FY2023 financials of acquired Opus Inc.; net loss $9.75M, cash $180k

Opus Genetics, Inc.

FY2023 audited: net loss $9.75M, no revenue; accumulated deficit $25.1M.
Cash & equivalents only $0.18M at Dec 31, 2023; total liabilities $2.93M exceed assets $0.79M.
R&D spending $7.18M, G&A $2.72M; convertible notes and warrant liabilities of $1.12M at fair value.
Acquisition closed Oct 22, 2024; combined company renamed Opus Genetics, Inc. (ticker IRD).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.